Lundbeck says it is highly satisfied with 2008 results

Lundbeck’s 2008 financial performance was highly satisfactory, it has stated.

For the first time ever, the company’s revenue exceeded the DKK 11 billion mark (1.31 billion pounds), increasing by seven per cent.

The company explained the rise was driven by three of its products ? Cipralex, Ebixa and Azilect ? which saw sales grow of 18, 14 and 57 per cent respectively.

Its profit from operations was also up seven per cent to DKK 2,833 million.

President and chief executive officer of the firm Ulf Wiinberg asserted the firm had seen strong progression.

He further noted that the upcoming takeovers of Ovation and the in-house initiatives it has launched will provide it with a good starting point for achieving its goals.

“Our ambition is for Lundbeck to be the company that makes the biggest difference worldwide in the treatment of patients suffering from central nervous system disorders,” Mr Wiinberg commented.

The pharmaceutical company researches, develops, manufacturers, markets and sells products to treat a number of neurological disorders.

These include Parkinson’s disease, depression and schizophrenia.